Rabies Virus Alert: How This Dangerous Virus Spreads and How to Stay Safe July 1,2026

Rabies Virus is a viral zoonotic disease leading to acute encephalitis in humans and other animals, historically recognized as hydrophobia due to victims’ panic when presented with liquids.

Initial symptoms include fever, unusual sensations at the exposure site, followed by severe manifestations such as nausea, vomiting, agitation, hydrophobia, paralysis, confusion, and ultimately, loss of consciousness. Once clinical symptoms manifest, rabies is almost invariably fatal, with the incubation period ranging from one week to over a year, primarily influenced by the distance the virus must travel through peripheral nerves to the central nervous system.

The disease is caused by lyssaviruses, primarily the rabies virus and Australian bat lyssavirus, transmitted through bites or scratches from infected animals, with saliva being a key vector.

Though theoretically possible, transmission via unpasteurized milk remains unverified by substantial empirical evidence. Globally, dogs are the most frequent source of rabies in humans, accounting for over 99% of cases in dog-endemic regions, while bat bites dominate in the Americas, constituting less than 5% of cases traced to dogs. Notably, diagnosis can only occur post-symptom onset.

Animal control and vaccination initiatives have notably reduced rabies risks from dogs globally. Pre-exposure vaccination for high-risk groups, including bat workers and individuals in rabies-prevalent regions, is advisable. For individuals who have been exposed, timely administration of the rabies virus vaccine and rabies immunoglobulin can prevent the disease if initiated before symptoms arise. Additionally, washing bite sites with soap and water or detergent may reduce viral load and minimize transmission risks. As of 2016, only fourteen individuals were documented to have survived after showing symptoms of rabies.

Globally, rabies is responsible for approximately 59,000 deaths annually, with 40% of fatalities occurring in children under 15 years, predominantly in Africa and Asia, where more than 95% of deaths from the disease occur. Rabies exists in over 150 countries and on all continents except Antarctica, affecting over 3 billion people in endemic regions.

Conversely, several countries, including Australia, Japan, and much of Western Europe, have eliminated rabies in dog populations, with various Pacific islands being rabies-free. It is recognized as a neglected tropical disease, with an estimated global economic impact of around US$8.6 billion annually due to lost lives, medical expenses, and psychological effects.

The History and Etymology of Rabies

The term “rabies virus ” originates from the Latin word “rabies,” which translates to ‘madness.’ In Greek, the word λῠ́σσᾰ (lyssa), also meaning ‘madness,’ is believed to be derived from either a feminine form of λῠ́κoς (lykos, meaning ‘wolf’) or from the Proto-Indo-European root *lewk-, which denotes ‘light.’ This Greek term is reflected in the genus name of the rabies virus, known as Lyssavirus.

Signs and symptoms

The incubation period for rabies in humans generally spans one to three months from the point of infection until the emergence of initial symptoms. These initial symptoms, which often appear nonspecific, may include fever and headache. As the disease advances, it provokes inflammation of the brain and the meninges, leading to a range of more severe symptoms such as partial paralysis, anxiety, insomnia, confusion, agitation, abnormal behavior, paranoia, terror, and hallucinations. A notable symptom that may develop during this stage is hydrophobia, or fear of water.

As rabies continues to progress, the affected individual may experience delirium and ultimately coma. The prognosis is grim; death typically occurs within two to ten days following the onset of initial symptoms. Once symptoms have manifested, survival becomes exceedingly rare, even with the provision of intensive medical care.

The incubation period for rabies in humans generally spans one to three months from the point of infection until the emergence of initial symptoms. These initial symptoms, which often appear nonspecific, may include fever and headache. As the disease advances, it provokes inflammation of the brain and the meninges, leading to a range of more severe symptoms such as partial paralysis, anxiety, insomnia, confusion, agitation, abnormal behavior, paranoia, terror, and hallucinations. A notable symptom that may develop during this stage is hydrophobia, or fear of water.

As rabies virus continues to progress, the affected individual may experience delirium and ultimately coma. The prognosis is grim; death typically occurs within two to ten days following the onset of initial symptoms. Once symptoms have manifested, survival becomes exceedingly rare, even with the provision of intensive medical care.

Cause of Rabies Virus

Rabies virus is a viral disease caused by lyssaviruses, specifically the rabies virus and Australian bat lyssavirus. The rabies virus, part of the Lyssavirus genus within the Rhabdoviridae family, features helical symmetry, measuring approximately 180 nm in length and 75 nm in cross-section.

These enveloped virions contain a single-stranded RNA genome with negative polarity, organized into a ribonucleoprotein complex that tightly binds the RNA with viral nucleoproteins. The viral genome encodes five highly conserved genes: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and viral RNA polymerase (L).

The Rabies virus enters host cells via trimeric spikes that interact with cell receptors, primarily acetylcholine receptors, leading to pinocytosis. Once inside, it exploits the endosomal acidic environment to release its RNA and proteins into the cytoplasm. The viral L protein transcribes the negative-strand RNA genome into five mRNA strands and a positive RNA strand using cytoplasmic nucleotides. These mRNAs are then translated into their respective proteins at cytoplasmic ribosomes. The glycoprotein (G) undergoes extensive modifications, including glycosylation in the Golgi apparatus.

As viral proteins accumulate, the polymerase synthesizes new negative RNA strands from the positive-strand template. These strands associate with nucleoproteins and travel to the inner cell membrane, where the glycoprotein, embedded in the membrane, wraps around the protein complexes, forming the new envelope. The virus then buds off from the host cell.

Neurotropic in nature, the rabies virus primarily infects muscle cells near the infection site, allowing it to replicate undetected by the immune system. Following sufficient replication, the virus binds to acetylcholine receptors at neuromuscular junctions and travels through nerve cell axons via retrograde transport, facilitated by its P protein interacting with dynein.

Upon reaching the central nervous system (CNS), the virus replicates in motor neurons and rapidly migrates to the brain. Eventually, it propagates centrifugally through the peripheral and autonomic nervous systems, reaching the salivary glands for transmission to new hosts.

Modes of Rabies Transmission

Rabies virus is a viral disease primarily affecting warm-blooded species, including humans. Historically, birds were infected with the virus in 1884, but they typically do not show symptoms and can recover. While rabies antibodies have been observed in some bird species after consuming rabies-infected mammals, the primary transmission to humans is through domestic dogs, accounting for approximately 99% of cases. Other animals, including bats, raccoons, foxes, monkeys, and various carnivores, can also transmit rabies, while small rodents and lagomorphs generally do not carry the virus.

Transmission usually occurs through bites from an infected animal, which may display aggressive behavior, attributed to the virus’s influence on its host. Following a bite, the virus enters the peripheral nervous system and travels to the central nervous system, evading detection during its early phase; timely vaccination may still provide immunity. Once the virus reaches the brain, it leads to encephalitis, marking the onset of symptoms. Post-symptomatic treatment is largely ineffective, with mortality rates exceeding 99%.

While there exists a theoretical possibility for human-to-human transmission, documented cases are rare and typically involve organ transplants, primarily corneal transplants. Casual contact with an infected individual does not pose a risk for transmission, nor does contact with non-infectious fluids or tissues. Research also identified rabies virus in South African Cape fur seals, indicating a potential outbreak in marine mammals. The complexity and rapid progression of rabies underscore the importance of prevention and timely medical intervention.

Diagnosis

Rabies virus presents significant diagnostic challenges due to its early symptoms, which can mimic other illnesses or aggressive behavioral changes. The preferred diagnostic method is the fluorescent antibody test (FAT), endorsed by the World Health Organization (WHO).

This immunohistochemistry technique employs a detector molecule, usually fluorescein isothiocyanate, combined with rabies-specific antibodies. It enables the identification of rabies antigens through fluorescent microscopy, making it a quick and cost-effective approach regardless of the sample’s geographical origin and host status. However, autolysed specimens can impede the sensitivity and specificity of the test.

Additionally, reverse transcription polymerase chain reaction (RT PCR) assays have emerged as sensitive and specific diagnostic tools, particularly beneficial for analyzing decomposed or archival samples. While brain tissue samples taken post-mortem provide reliable diagnoses, alternative bodily fluids, such as saliva, urine, and cerebrospinal fluid, offer less sensitivity.

Negri bodies, which are cerebral inclusion bodies, serve as definitive evidence of rabies infection but are present in only around 80% of cases. If feasible, examining the animal that delivered the bite is also advised to confirm rabies presence.

Alternative light microscopy techniques are lower in cost and can facilitate rabies diagnosis in less-developed regions. The LN34 test, developed by the Centers for Disease Control and Prevention (CDC) in 2018, simplifies analysis of a deceased animal’s brain, aiding in post-exposure prevention decisions.

For suspected human rabies virus cases, differential diagnosis should encompass several causes of encephalitis, particularly infections from herpesviruses, enteroviruses, and arboviruses like West Nile virus. Key viral considerations include herpes simplex virus type one, varicella zoster virus, and occasionally, various enteroviruses, including coxsackieviruses, echoviruses, polioviruses, and human enteroviruses 68 to 71.

Rabies Prevention

Almost all human exposure to rabies virus was fatal until the development of a vaccine in 1885 by Louis Pasteur and Émile Roux. Their innovative vaccine was derived from infected rabbit nerve tissue, which was weakened through a drying process lasting five to ten days. While similar nerve tissue vaccines continue to be utilized in some countries due to their cost-effectiveness, the human diploid cell rabies vaccine was initiated in 1967, followed by the introduction of more affordable alternatives, such as the purified chicken embryo cell vaccine and the purified vero cell rabies vaccine.

In efforts to combat rabies outbreaks in undomesticated animals, a recombinant vaccine known as V-RG has been deployed in various regions, including Belgium, France, Germany, and the United States. Additionally, immunization prior to exposure is now common practice among both human and nonhuman populations, and many jurisdictions mandate that domesticated animals receive vaccinations to prevent the spread of rabies.

The Missouri Department of Health and Senior Services Communicable Disease Surveillance 2007 Annual Report highlights several measures to mitigate the risk of rabies contraction. Key recommendations include vaccinating domestic animals such as dogs, cats, and ferrets; supervising pets; avoiding interaction with wild animals and strays; and reporting any unusual behavior in wildlife to animal control. In case of bites, immediate washing of the wound with soap and water for 10 to 15 minutes is advised, followed by consulting a healthcare provider for potential post-exposure prophylaxis.

Observations indicate that in various regions including Asia and parts of the Americas and Africa, dogs are the primary rabies carriers, with mandatory vaccination being less effective in rural areas. In developing countries, the impracticality of pet ownership may complicate vaccination efforts.

Instead, oral vaccination bait distribution has been successfully employed in several locations, notably Canada, Europe, and the United States, effectively reducing rabies incidence in rural settings. For instance, in Montreal, Quebec, baited oral vaccines have targeted raccoons in urban parks, demonstrating a viable strategy.

Although vaccination campaigns can be costly, cost-benefit analyses suggest that such baiting methods could be an economical approach to rabies control. This is supported by dramatic decreases in rabies virus cases in Ontario after initiating aerial bait-vaccination campaigns.

The overall incidence of rabies-related human fatalities in the United States has significantly decreased from 100 or more annually in the early 20th century to one or two cases per year today, primarily due to comprehensive vaccination of domestic pets and advancements in human vaccines and immunoglobulin therapies. Most recent mortalities are attributed to unnoticed bat bites, resulting in untreated rabies cases. Additionally, September 28 is recognized as World Rabies Day, emphasizing the importance of awareness, prevention, and disease elimination.

Treatment of Rabies Virus

Treatment after Exposure

Treatment following potential rabies exposure is highly effective if administered within 10 days, with the rabies vaccine achieving 100% efficacy before the onset of symptoms. Annually, over 29 million individuals receive post-exposure vaccinations, although the associated costs can be significant. In the United States, a typical post-exposure regimen includes one dose of human rabies immunoglobulin (HRIG) and four doses of the rabies vaccine over 14 days.

The expenses for HRIG are substantial, sometimes reaching several thousand dollars; for instance, in the UK, a single dose costs the National Health Service £1,000. The full vaccine course is priced between £120 and £180. It is crucial for HRIG to be administered as close to the bite as possible, with the remaining dose given intramuscularly at a different site.

Individuals previously vaccinated against rabies are exempt from receiving immunoglobulin and only require vaccinations on days 0 and 3. The side effects observed with modern cell-based vaccines are akin to those of flu vaccines, contrasting with older nerve-tissue vaccinations, which necessitated multiple painful abdominal injections but were less expensive. The latter is being replaced by more affordable intradermal vaccination regimens recommended by the World Health Organization. In infants under one year, the lateral thigh is the preferred injection site.

Immediate wound care—washing with soap and water for around five minutes—effectively decreases viral load, with subsequent application of povidone-iodine or alcohol recommended for further viral reduction. Encountering a bat, particularly in locations where a child or vulnerable person has been unattended, qualifies as an indication for post-exposure prophylaxis (PEP). While cost-benefit analyses have questioned the precautionary administration of PEP when no contact is evident, studies support its use when a child or mentally disabled person has been alone with a bat in areas like bedrooms, where unnoticed bites could occur.

The administration of the rabies virus’s vaccine has evolved; it no longer involves painful abdominal injections and is now given as intramuscular shots in the upper arm. Concerns regarding the pain associated with PEP can deter timely medical treatment for those exposed to rabies, highlighting a significant public health issue.

After the Onset of Symptoms

Once rabies develops, prognosis is dire, with death almost inevitable. Palliative care is advised in hospitals, focusing on pain management through large doses of medication and sedatives, rather than physical restraints. While ice fragments may provide relief for thirst, there is insufficient evidence to indicate that intravenous hydration enhances comfort or prolongs life for patients receiving palliative care.

The Milwaukee Protocol represents a treatment approach that places rabies-symptomatic patients into a chemically induced coma while administering antiviral drugs to protect the brain, aiming to allow time for the body to generate rabies antibodies. This method was notably employed in 2004 on Jeanna Giese, a teenage girl from Wisconsin, marking her as the first known survivor of rabies without prior post-exposure prophylaxis.

Despite her survival, Giese underwent significant rehabilitation, with lasting impairments to her balance and neural functions. Although the protocol has been attempted on other rabies victims, its overall effectiveness has been criticized; fatalities have occurred even among those who initially survived the acute phase. Ethical concerns have been raised regarding its high costs and the nature of survival claims, as a 2025 report suggested that some individuals counted as survivors may not have experienced true rabies progression to the antibody stage, questioning the validity of reported successes.

Research into antiviral treatments has also progressed, with drugs like favipiravir showing promise in inhibiting the onset of encephalitis associated with rabies. Combining such antiviral therapies with immunotherapy and neuroprotective interventions have been proposed as potentially beneficial strategies against rabies infection.

Recovery and Prognosis of Rabies

In 2010, approximately 26,000 fatalities due to rabies Virus were reported globally, a significant decrease from the estimated 54,000 deaths in 1990. The bulk of these rabies-related deaths occurred in Asia and Africa, indicating a persistent public health challenge in these regions. By 2015, India accounted for the highest number of rabies cases, with approximately 20,847 reported deaths attributed to the disease.

Following India, China reported around 6,000 cases, while the Democratic Republic of the Congo documented approximately 5,600 cases. In response to this ongoing health threat, a collaboration initiated in 2015 involving the World Health Organization (WHO), the World Organization for Animal Health (OIE), the Food and Agriculture Organization of the United Nations (FAO), and the Global Alliance for Rabies Control set an ambitious objective of eliminating rabies-related deaths by the year 2030. This initiative underscores the global commitment to combating rabies and improving public health outcomes in affected countries.

Global Epidemiology of Rabies

Rabies Virus in Australia

Australia holds an official status of being rabies-free; however, it is noteworthy that the Australian bat lyssavirus (ABLV), identified in 1996, poses a risk as it is a rabies-causing virus associated with indigenous bat populations in Australia. This virus is related to the more widely recognized rabies virus.

Rabies Virus in India

India leads the world in human rabies cases, attributed mainly to an increase in stray dog populations following a 2001 law that prohibited their euthanization. The situation is compounded by a psychosomatic condition known as puppy pregnancy syndrome (PPS), where dog bite victims, regardless of gender, mistakenly believe they are carrying puppies.

This misconception often drives them to seek out alternative remedies from faith healers instead of pursuing necessary medical treatment. As a result, approximately 20,000 individuals succumb to rabies annually in India, accounting for over one-third of all rabies-related fatalities worldwide.

Rabies Virus in United States

Canine-specific rabies has been eradicated in the United States, yet the virus remains prevalent among wild animals, with approximately 100 dogs infected by wildlife annually. High levels of public awareness, proactive vaccination of domestic pets, control of feral animal populations, and accessibility of postexposure prophylaxis have significantly reduced human rabies cases.

Between 1960 and 2018, 125 human rabies cases were documented in the U.S., with 36 (28%) resulting from dog bites during international travel. Of the 89 domestic infections, bats were responsible for 62 cases (70%). Notably, a case of rabies was reported in a feral cat from a colony of 20 in Maryland in 2025.

Rabies in Europe and Maxico

In Europe, rabies cases are rare, occurring both in travelers and locally. Switzerland successfully eliminated rabies by distributing chicken heads laced with a live attenuated vaccine in the Swiss Alps, which were consumed by foxes, the primary rabies carriers in the region. After being declared rabies-free from 1997 to 2008, Italy experienced a resurgence due to an epidemic in neighboring Balkans, affecting areas in Triveneto. Following a comprehensive vaccination campaign, Italy regained its rabies-free status in 2013, with the last case reported in a red fox in 2011.

The United Kingdom has been rabies-free since the early 20th century, apart from rare instances of a rabies-like virus (EBLV-2) in Daubenton’s bats, which has caused one human fatality. Since 2000, there have been six rabies-related deaths attributed to infections acquired abroad, with the last indigenous rabies case dated back to 1922 and the last death in 1902.

Sweden and mainland Norway have not reported rabies since 1886, although bat rabies antibodies have been detected in local bats, with concerns raised about potential transmission via Arctic migratory routes. Additionally, five documented human fatalities linked to lyssaviruses carried by bats have occurred across Europe, involving cases from 1977 in Ukraine to France in 2019.

In Mexico, the World Health Organization designated the country as free of dog-transmitted rabies in 2019, noting no dog-human rabies transmission cases in the preceding two years. This marked a significant achievement in public health and rabies control efforts.

Rabies in Asian Countries

Rabies Virus, although preventable with several successful initiatives in regions like North America, South Korea, and Western Europe, continues to be endemic in numerous southern and eastern Asian countries, including Cambodia, Bangladesh, Bhutan, North Korea, India, Indonesia, Myanmar, Nepal, Sri Lanka, and Thailand.

Southeast Asia accounts for approximately half of the global rabies fatalities, translating to about 26,000 deaths annually. A significant barrier to implementing effective rabies control measures in these regions is financial constraints. The primary preventive strategy—treating wild canines—is notably expensive, costing roughly ten times more than treating human bite victims. Consequently, nations like India struggle to adopt many necessary preventative actions due to these economic limitations.